Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension
NCT01971450 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 89
Last updated 2019-03-26
Summary
Local, prospective, multicenter, non-comparative, non-interventional, observational study. It is planed to assess compliance of patients with PH (pulmonary hypertension) with the physician's recommendation in real practice.
Conditions
- Hypertension, Pulmonary
Interventions
- DRUG
-
Iloprost (Ventavis, BAYQ6256)
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bayer Study Director · Bayer
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-11-21
- Primary Completion
- 2017-06-28
- Completion
- 2018-04-18
Countries
- Russia
More Related Trials
-
Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension
NCT00185315 ·Status: COMPLETED ·Phase: PHASE3
-
Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients
NCT01781052 ·Status: COMPLETED
-
Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)
NCT00882947 ·Status: COMPLETED
-
Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System
NCT01468545 ·Status: COMPLETED
-
Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension
NCT00414687 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)
NCT01437878 ·Status: TERMINATED ·Phase: PHASE2
-
Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension
NCT03293407 ·Status: COMPLETED
-
Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)
NCT02825160 ·Status: COMPLETED
-
Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years
NCT01389271 ·Status: COMPLETED
-
Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)
NCT02826252 ·Status: COMPLETED
-
Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension
NCT01054105 ·Status: COMPLETED
-
Ventavis® Registry Protocol
NCT00902603 ·Status: TERMINATED
-
Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis
NCT00109681 ·Status: COMPLETED ·Phase: PHASE2
-
Iloprost-Study: Comparison of Nitric Oxide to Iloprost (Ventavis) for Treatment of Pulmonary Hypertension in Children After Cardiopulmonary Bypass Surgery
NCT00235521 ·Status: COMPLETED ·Phase: NA
-
Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction
NCT00458042 ·Status: TERMINATED ·Phase: PHASE4
-
The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting
NCT00467896 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension
NCT00453414 ·Status: WITHDRAWN ·Phase: PHASE2
-
Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects
NCT00741819 ·Status: COMPLETED ·Phase: PHASE4
-
Iloprost in High Risk Cardiac Surgical Patients
NCT00927654 ·Status: COMPLETED ·Phase: PHASE3
-
Comparative PK PD Study in PAH Patients (Fox vs. I-Neb)
NCT02032836 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.
NCT00640315 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide
NCT04231084 ·Status: COMPLETED ·Phase: PHASE4
-
Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension
NCT00709098 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
NCT05747508 ·Status: UNKNOWN ·Phase: PHASE2
-
Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD
NCT01728220 ·Status: COMPLETED ·Phase: PHASE2